Fulcrum Therapeutics Inc. (FULC) NASDAQ
$9.44 (0.02) (-0.21%)
Market Cap: $585.91M
As of 03/28/24 04:00 PM EDT. Market closed.
Fulcrum Therapeutics Inc. (FULC)
NASDAQ
$9.44
(0.02) (-0.21%)
Market Cap: $585.91M
As of 03/28/24 04:00 PM EDT. Market closed.
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their ... read more
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Tourangeau Greg | Vice President, Finance | Mar 08, 2024 | Sale | $11.72 | 4,884 | 57,219 | 11,807 | Mar 08, 2024, 06:05 PM |
Tourangeau Greg | Principal Accounting Officer | May 10, 2023 | Sale | $3.31 | 210 | 695 | 15,992 | May 11, 2023, 04:12 PM |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Jan 20, 2023 | Buy | $13.00 | 1,923,076 | 24,999,988 | 11,609,704 | Jan 24, 2023, 04:30 PM |
Gould Robert J | Interim President & CEO | Jan 13, 2023 | Sale | $15.00 | 6,766 | 101,490 | 499,864 | Jan 13, 2023, 06:33 PM |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Jan 04, 2023 | Buy | $7.28 | 180,703 | 1,314,806 | 9,686,628 | Jan 06, 2023, 04:39 PM |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Dec 27, 2022 | Buy | $5.99 | 4,089 | 24,510 | 9,505,925 | Dec 29, 2022, 05:00 PM |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Dec 19, 2022 | Buy | $5.90 | 98,787 | 582,814 | 9,501,836 | Dec 21, 2022, 04:30 PM |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Dec 16, 2022 | Buy | $5.42 | 1,341,420 | 7,269,826 | 9,403,049 | Dec 16, 2022, 04:41 PM |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Dec 15, 2022 | Buy | $5.49 | 237,029 | 1,302,474 | 8,061,629 | Dec 16, 2022, 04:41 PM |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Dec 14, 2022 | Buy | $5.46 | 824,600 | 4,501,574 | 7,824,600 | Dec 16, 2022, 04:41 PM |
Gould Robert J | Director | Jun 07, 2022 | Option Exercise | $7.84 | 71,435 | 560,050 | 578,065 | Jun 08, 2022, 07:33 PM |
Gould Robert J | Director | Jun 07, 2022 | Sale | $8.09 | 71,435 | 577,895 | 506,630 | Jun 08, 2022, 07:33 PM |
Gould Robert J | Director | Jun 06, 2022 | Option Exercise | $7.84 | 24,382 | 191,155 | 531,012 | Jun 06, 2022, 07:00 PM |
Gould Robert J | Director | Jun 03, 2022 | Option Exercise | $7.84 | 25,551 | 200,320 | 532,181 | Jun 06, 2022, 07:00 PM |
Gould Robert J | Director | Jun 02, 2022 | Option Exercise | $7.84 | 16,689 | 130,842 | 523,319 | Jun 06, 2022, 07:00 PM |
Gould Robert J | Director | Jun 03, 2022 | Sale | $7.95 | 25,551 | 203,056 | 506,630 | Jun 06, 2022, 07:00 PM |
Gould Robert J | Director | Jun 02, 2022 | Sale | $7.92 | 16,689 | 132,162 | 506,630 | Jun 06, 2022, 07:00 PM |
Gould Robert J | Director | Jun 06, 2022 | Sale | $8.10 | 24,382 | 197,592 | 506,630 | Jun 06, 2022, 07:00 PM |
Gould Robert J | Director | Apr 07, 2022 | Option Exercise | $7.84 | 5,631 | 44,147 | 512,261 | Apr 11, 2022, 05:00 PM |
Gould Robert J | Director | Apr 07, 2022 | Sale | $24.01 | 5,631 | 135,228 | 506,630 | Apr 11, 2022, 05:00 PM |
Gould Robert J | Director | Apr 05, 2022 | Option Exercise | $7.84 | 52,552 | 412,008 | 559,182 | Apr 05, 2022, 07:00 PM |
Gould Robert J | Director | Apr 04, 2022 | Option Exercise | $7.84 | 7,235 | 56,722 | 513,865 | Apr 05, 2022, 07:00 PM |
Gould Robert J | Director | Apr 01, 2022 | Option Exercise | $7.84 | 34,464 | 270,198 | 541,094 | Apr 05, 2022, 07:00 PM |
Gould Robert J | Director | Apr 05, 2022 | Sale | $24.26 | 52,552 | 1,274,775 | 506,630 | Apr 05, 2022, 07:00 PM |
Gould Robert J | Director | Apr 04, 2022 | Sale | $24.02 | 7,235 | 173,749 | 506,630 | Apr 05, 2022, 07:00 PM |
Gould Robert J | Director | Apr 01, 2022 | Sale | $24.03 | 34,464 | 828,160 | 506,630 | Apr 05, 2022, 07:00 PM |
Moxham Christopher | Chief Scientific Officer | Aug 10, 2021 | Option Exercise | $7.84 | 51,785 | 405,994 | 31,071 | Aug 12, 2021, 04:20 PM |
Moxham Christopher | Chief Scientific Officer | Aug 10, 2021 | Sale | $17.60 | 51,785 | 911,416 | 0 | Aug 12, 2021, 04:20 PM |
Stuart Bryan | See Remarks | Aug 11, 2021 | Option Exercise | $7.84 | 28,000 | 219,520 | 28,000 | Aug 12, 2021, 04:20 PM |
Stuart Bryan | See Remarks | Aug 10, 2021 | Option Exercise | $7.84 | 32,000 | 250,880 | 32,000 | Aug 12, 2021, 04:20 PM |
Stuart Bryan | See Remarks | Aug 11, 2021 | Sale | $23.75 | 28,000 | 665,000 | 0 | Aug 12, 2021, 04:20 PM |
Stuart Bryan | See Remarks | Aug 10, 2021 | Sale | $17.50 | 32,000 | 560,000 | 0 | Aug 12, 2021, 04:20 PM |
Oltmans Curtis Gale | SVP, General Counsel | Jun 28, 2021 | Buy | $9.01 | 1,088 | 9,803 | 1,088 | Jun 29, 2021, 04:16 PM |
Thomson Peter G. | VP Finance & Accounting | Jun 28, 2021 | Buy | $9.00 | 2,300 | 20,700 | 2,300 | Jun 29, 2021, 04:15 PM |
GERAGHTY JAMES A | Director | Jun 28, 2021 | Buy | $9.16 | 10,000 | 91,600 | 90,714 | Jun 29, 2021, 04:15 PM |
Gould Robert J | See Remarks | Mar 16, 2021 | Sale | $12.43 | 789 | 9,806 | 506,630 | Mar 17, 2021, 04:30 PM |
Gould Robert J | See Remarks | Mar 15, 2021 | Sale | $12.13 | 9,211 | 111,773 | 507,419 | Mar 17, 2021, 04:30 PM |
Thomson Peter G. | VP Finance & Accounting | Feb 22, 2021 | Option Exercise | $7.84 | 5,000 | 39,200 | 20,212 | Feb 24, 2021, 04:30 PM |
Thomson Peter G. | VP Finance & Accounting | Feb 22, 2021 | Sale | $14.72 | 5,000 | 73,582 | 15,212 | Feb 24, 2021, 04:30 PM |
Gould Robert J | See Remarks | Feb 16, 2021 | Sale | $14.27 | 8,215 | 117,197 | 518,303 | Feb 18, 2021, 04:30 PM |
Thomson Peter G. | VP Finance & Accounting | Jan 21, 2021 | Sale | $14.00 | 6,607 | 92,498 | 15,212 | Jan 25, 2021, 04:30 PM |
Gould Robert J | See Remarks | Jan 20, 2021 | Sale | $12.08 | 10,000 | 120,826 | 524,845 | Jan 22, 2021, 04:30 PM |
Wallace Owen B. | Chief Scientific Officer | Sep 14, 2020 | Option Exercise | $7.84 | 6,350 | 49,784 | 133,438 | Sep 14, 2020, 04:19 PM |
Wallace Owen B. | Chief Scientific Officer | Jul 08, 2020 | Option Exercise | $7.84 | 2,951 | 23,136 | 130,039 | Jul 09, 2020, 04:18 PM |
Wallace Owen B. | Chief Scientific Officer | Jul 08, 2020 | Sale | $20.00 | 2,951 | 59,020 | 127,088 | Jul 09, 2020, 04:18 PM |
Gould Robert J | See Remarks | Jul 08, 2020 | Sale | $20.00 | 2,500 | 50,000 | 534,845 | Jul 09, 2020, 04:15 PM |
Cadavid Diego | SVP Clinical Development | Jul 01, 2020 | Sale | $18.30 | 1,071 | 19,599 | 65,714 | Jul 02, 2020, 12:00 AM |
Wallace Owen B. | Chief Scientific Officer | Jun 30, 2020 | Option Exercise | $7.84 | 141 | 1,105 | 127,229 | Jul 01, 2020, 04:39 PM |
Wallace Owen B. | Chief Scientific Officer | Jun 30, 2020 | Sale | $20.00 | 141 | 2,820 | 127,088 | Jul 01, 2020, 04:39 PM |
Cadavid Diego | SVP Clinical Development | Jun 25, 2020 | Option Exercise | $4.83 | 1,459 | 7,047 | 68,244 | Jun 26, 2020, 04:17 PM |
Cadavid Diego | SVP Clinical Development | Jun 25, 2020 | Sale | $22.00 | 1,459 | 32,098 | 66,785 | Jun 26, 2020, 04:17 PM |
Gould Robert J | See Remarks | Jun 25, 2020 | Sale | $20.80 | 2,500 | 51,992 | 537,345 | Jun 26, 2020, 04:15 PM |
Cadavid Diego | SVP Clinical Development | Jun 10, 2020 | Option Exercise | $4.83 | 401 | 1,937 | 67,186 | Jun 12, 2020, 05:10 PM |
Cadavid Diego | SVP Clinical Development | Jun 10, 2020 | Sale | $22.00 | 401 | 8,822 | 66,785 | Jun 12, 2020, 05:10 PM |
Gould Robert J | See Remarks | Jun 09, 2020 | Sale | $20.00 | 156 | 3,120 | 539,845 | Jun 10, 2020, 04:15 PM |
Gould Robert J | See Remarks | Jun 05, 2020 | Sale | $20.17 | 3,433 | 69,251 | 540,001 | Jun 09, 2020, 04:16 PM |
Cadavid Diego | SVP Clinical Development | Jun 04, 2020 | Option Exercise | $4.83 | 226 | 1,092 | 67,011 | Jun 08, 2020, 04:17 PM |
Cadavid Diego | SVP Clinical Development | Jun 05, 2020 | Option Exercise | $4.83 | 451 | 2,178 | 67,236 | Jun 08, 2020, 04:17 PM |
Cadavid Diego | SVP Clinical Development | Jun 05, 2020 | Sale | $20.18 | 451 | 9,101 | 66,785 | Jun 08, 2020, 04:17 PM |
Cadavid Diego | SVP Clinical Development | Jun 04, 2020 | Sale | $20.05 | 226 | 4,531 | 66,785 | Jun 08, 2020, 04:17 PM |
Gould Robert J | See Remarks | Jun 04, 2020 | Sale | $20.04 | 1,300 | 26,058 | 543,434 | Jun 05, 2020, 04:26 PM |
Gould Robert J | See Remarks | Jun 03, 2020 | Sale | $20.13 | 1,500 | 30,192 | 544,734 | Jun 05, 2020, 04:26 PM |
Cadavid Diego | SVP Clinical Development | Jun 02, 2020 | Option Exercise | $4.83 | 45 | 217 | 66,830 | Jun 04, 2020, 04:16 PM |
Cadavid Diego | SVP Clinical Development | Jun 03, 2020 | Option Exercise | $4.83 | 338 | 1,633 | 67,123 | Jun 04, 2020, 04:16 PM |
Cadavid Diego | SVP Clinical Development | Jun 03, 2020 | Sale | $20.18 | 338 | 6,820 | 66,785 | Jun 04, 2020, 04:16 PM |
Cadavid Diego | SVP Clinical Development | Jun 02, 2020 | Sale | $20.00 | 45 | 900 | 66,785 | Jun 04, 2020, 04:16 PM |
Gould Robert J | See Remarks | Jun 02, 2020 | Sale | $20.00 | 2,797 | 55,940 | 546,234 | Jun 03, 2020, 04:17 PM |
Gould Robert J | See Remarks | Jun 01, 2020 | Sale | $20.00 | 5 | 100 | 549,031 | Jun 03, 2020, 04:17 PM |
Cadavid Diego | SVP Clinical Development | May 29, 2020 | Option Exercise | $4.83 | 200 | 966 | 66,985 | Jun 01, 2020, 04:16 PM |
Cadavid Diego | SVP Clinical Development | May 28, 2020 | Option Exercise | $4.83 | 600 | 2,898 | 67,385 | Jun 01, 2020, 04:16 PM |
Cadavid Diego | SVP Clinical Development | May 29, 2020 | Sale | $20.03 | 200 | 4,007 | 66,785 | Jun 01, 2020, 04:16 PM |
Cadavid Diego | SVP Clinical Development | May 28, 2020 | Sale | $20.00 | 600 | 12,000 | 66,785 | Jun 01, 2020, 04:16 PM |
Gould Robert J | See Remarks | May 29, 2020 | Sale | $20.08 | 1,390 | 27,911 | 549,036 | Jun 01, 2020, 04:15 PM |
Gould Robert J | See Remarks | May 28, 2020 | Sale | $20.01 | 1,919 | 38,391 | 550,426 | Jun 01, 2020, 04:15 PM |
Wallace Owen B. | Chief Scientific Officer | May 28, 2020 | Option Exercise | $7.84 | 2,232 | 17,499 | 129,320 | Jun 01, 2020, 04:15 PM |
Wallace Owen B. | Chief Scientific Officer | May 28, 2020 | Sale | $20.00 | 2,232 | 44,640 | 127,088 | Jun 01, 2020, 04:15 PM |
Wallace Owen B. | Chief Scientific Officer | May 27, 2020 | Option Exercise | $7.84 | 448 | 3,512 | 127,536 | May 29, 2020, 04:15 PM |
Wallace Owen B. | Chief Scientific Officer | May 27, 2020 | Sale | $20.00 | 448 | 8,960 | 127,088 | May 29, 2020, 04:15 PM |
Wallace Owen B. | Chief Scientific Officer | May 26, 2020 | Option Exercise | $7.84 | 412 | 3,230 | 127,500 | May 28, 2020, 04:16 PM |
Wallace Owen B. | Chief Scientific Officer | May 26, 2020 | Sale | $20.00 | 412 | 8,240 | 127,088 | May 28, 2020, 04:16 PM |
Gould Robert J | See Remarks | May 26, 2020 | Sale | $20.00 | 2,500 | 50,000 | 552,345 | May 28, 2020, 04:15 PM |
Cadavid Diego | SVP Clinical Development | May 12, 2020 | Option Exercise | $4.83 | 1,860 | 8,984 | 68,645 | May 12, 2020, 04:15 PM |
Cadavid Diego | SVP Clinical Development | May 12, 2020 | Sale | $18.00 | 1,860 | 33,480 | 66,785 | May 12, 2020, 04:15 PM |
Thomson Peter G. | VP Finance & Accounting | May 11, 2020 | Sale | $16.00 | 7,500 | 120,000 | 21,071 | May 12, 2020, 04:15 PM |
Cadavid Diego | SVP Clinical Development | Mar 02, 2020 | Sale | $17.38 | 2,143 | 37,255 | 67,100 | Mar 02, 2020, 06:42 PM |
Thomson Peter G. | VP Finance & Accounting | Feb 24, 2020 | Sale | $16.83 | 5,000 | 84,153 | 30,923 | Feb 26, 2020, 07:52 PM |
Gould Robert J | See Remarks | Feb 19, 2020 | Sale | $20.00 | 2,500 | 50,000 | 554,845 | Feb 20, 2020, 04:24 PM |
Wallace Owen B. | Chief Scientific Officer | Feb 19, 2020 | Option Exercise | $7.84 | 6,088 | 47,730 | 133,176 | Feb 20, 2020, 04:23 PM |
Wallace Owen B. | Chief Scientific Officer | Feb 19, 2020 | Sale | $20.00 | 6,088 | 121,760 | 127,088 | Feb 20, 2020, 04:23 PM |
Cadavid Diego | SVP Clinical Development | Feb 03, 2020 | Sale | $17.33 | 2,143 | 37,142 | 68,928 | Feb 05, 2020, 04:31 PM |
Thomson Peter G. | VP Finance & Accounting | Jan 23, 2020 | Sale | $17.22 | 5,000 | 86,102 | 33,833 | Jan 27, 2020, 04:28 PM |
Sanofi | 10% Owner | Jul 22, 2019 | Buy | $16.00 | 93,750 | 1,500,000 | 558,035 | Jul 23, 2019, 11:39 AM |
Third Rock Ventures IV, L.P. | 10% Owner | Jul 22, 2019 | Buy | $16.00 | 81,250 | 1,300,000 | 2,343,154 | Jul 22, 2019, 04:38 PM |
Third Rock Ventures III, L.P. | 10% Owner | Jul 22, 2019 | Buy | $16.00 | 81,250 | 1,300,000 | 5,962,202 | Jul 22, 2019, 04:34 PM |
6 Dimensions Capital, L.P. | 10% Owner | Jul 22, 2019 | Buy | $16.00 | 118,750 | 1,900,000 | 559,821 | Jul 22, 2019, 04:32 PM |
Casdin Capital, LLC | 10% Owner | Jul 22, 2019 | Buy | $15.84 | 140,000 | 2,217,495 | 604,285 | Jul 22, 2019, 04:31 PM |
LEVIN MARK J | Director | Jul 22, 2019 | Buy | $16.00 | 81,250 | 1,300,000 | 5,962,202 | Jul 22, 2019, 04:31 PM |
Owner | Relationship | Date | Value($) |
Tourangeau Greg | Vice President, Finance | 03/08/2024 | 57,219 |
Tourangeau Greg | Principal Accounting Officer | 05/10/2023 | 695 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 01/20/2023 | 24,999,988 |
Gould Robert J | Interim President & CEO | 01/13/2023 | 101,490 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 01/04/2023 | 1,314,806 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 12/27/2022 | 24,510 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 12/19/2022 | 582,814 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 12/16/2022 | 7,269,826 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 12/15/2022 | 1,302,474 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 12/14/2022 | 4,501,574 |
Gould Robert J | Director | 06/07/2022 | 560,050 |
Gould Robert J | Director | 06/07/2022 | 577,895 |
Gould Robert J | Director | 06/06/2022 | 191,155 |
Gould Robert J | Director | 06/03/2022 | 200,320 |
Gould Robert J | Director | 06/02/2022 | 130,842 |
Gould Robert J | Director | 06/03/2022 | 203,056 |
Gould Robert J | Director | 06/02/2022 | 132,162 |
Gould Robert J | Director | 06/06/2022 | 197,592 |
Gould Robert J | Director | 04/07/2022 | 44,147 |
Gould Robert J | Director | 04/07/2022 | 135,228 |
Gould Robert J | Director | 04/05/2022 | 412,008 |
Gould Robert J | Director | 04/04/2022 | 56,722 |
Gould Robert J | Director | 04/01/2022 | 270,198 |
Gould Robert J | Director | 04/05/2022 | 1,274,775 |
Gould Robert J | Director | 04/04/2022 | 173,749 |
Gould Robert J | Director | 04/01/2022 | 828,160 |
Moxham Christopher | Chief Scientific Officer | 08/10/2021 | 405,994 |
Moxham Christopher | Chief Scientific Officer | 08/10/2021 | 911,416 |
Stuart Bryan | See Remarks | 08/11/2021 | 219,520 |
Stuart Bryan | See Remarks | 08/10/2021 | 250,880 |
Stuart Bryan | See Remarks | 08/11/2021 | 665,000 |
Stuart Bryan | See Remarks | 08/10/2021 | 560,000 |
Oltmans Curtis Gale | SVP, General Counsel | 06/28/2021 | 9,803 |
Thomson Peter G. | VP Finance & Accounting | 06/28/2021 | 20,700 |
GERAGHTY JAMES A | Director | 06/28/2021 | 91,600 |
Gould Robert J | See Remarks | 03/16/2021 | 9,806 |
Gould Robert J | See Remarks | 03/15/2021 | 111,773 |
Thomson Peter G. | VP Finance & Accounting | 02/22/2021 | 39,200 |
Thomson Peter G. | VP Finance & Accounting | 02/22/2021 | 73,582 |
Gould Robert J | See Remarks | 02/16/2021 | 117,197 |
Thomson Peter G. | VP Finance & Accounting | 01/21/2021 | 92,498 |
Gould Robert J | See Remarks | 01/20/2021 | 120,826 |
Wallace Owen B. | Chief Scientific Officer | 09/14/2020 | 49,784 |
Wallace Owen B. | Chief Scientific Officer | 07/08/2020 | 23,136 |
Wallace Owen B. | Chief Scientific Officer | 07/08/2020 | 59,020 |
Gould Robert J | See Remarks | 07/08/2020 | 50,000 |
Cadavid Diego | SVP Clinical Development | 07/01/2020 | 19,599 |
Wallace Owen B. | Chief Scientific Officer | 06/30/2020 | 1,105 |
Wallace Owen B. | Chief Scientific Officer | 06/30/2020 | 2,820 |
Cadavid Diego | SVP Clinical Development | 06/25/2020 | 7,047 |
Cadavid Diego | SVP Clinical Development | 06/25/2020 | 32,098 |
Gould Robert J | See Remarks | 06/25/2020 | 51,992 |
Cadavid Diego | SVP Clinical Development | 06/10/2020 | 1,937 |
Cadavid Diego | SVP Clinical Development | 06/10/2020 | 8,822 |
Gould Robert J | See Remarks | 06/09/2020 | 3,120 |
Gould Robert J | See Remarks | 06/05/2020 | 69,251 |
Cadavid Diego | SVP Clinical Development | 06/04/2020 | 1,092 |
Cadavid Diego | SVP Clinical Development | 06/05/2020 | 2,178 |
Cadavid Diego | SVP Clinical Development | 06/05/2020 | 9,101 |
Cadavid Diego | SVP Clinical Development | 06/04/2020 | 4,531 |
Gould Robert J | See Remarks | 06/04/2020 | 26,058 |
Gould Robert J | See Remarks | 06/03/2020 | 30,192 |
Cadavid Diego | SVP Clinical Development | 06/02/2020 | 217 |
Cadavid Diego | SVP Clinical Development | 06/03/2020 | 1,633 |
Cadavid Diego | SVP Clinical Development | 06/03/2020 | 6,820 |
Cadavid Diego | SVP Clinical Development | 06/02/2020 | 900 |
Gould Robert J | See Remarks | 06/02/2020 | 55,940 |
Gould Robert J | See Remarks | 06/01/2020 | 100 |
Cadavid Diego | SVP Clinical Development | 05/29/2020 | 966 |
Cadavid Diego | SVP Clinical Development | 05/28/2020 | 2,898 |
Cadavid Diego | SVP Clinical Development | 05/29/2020 | 4,007 |
Cadavid Diego | SVP Clinical Development | 05/28/2020 | 12,000 |
Gould Robert J | See Remarks | 05/29/2020 | 27,911 |
Gould Robert J | See Remarks | 05/28/2020 | 38,391 |
Wallace Owen B. | Chief Scientific Officer | 05/28/2020 | 17,499 |
Wallace Owen B. | Chief Scientific Officer | 05/28/2020 | 44,640 |
Wallace Owen B. | Chief Scientific Officer | 05/27/2020 | 3,512 |
Wallace Owen B. | Chief Scientific Officer | 05/27/2020 | 8,960 |
Wallace Owen B. | Chief Scientific Officer | 05/26/2020 | 3,230 |
Wallace Owen B. | Chief Scientific Officer | 05/26/2020 | 8,240 |
Gould Robert J | See Remarks | 05/26/2020 | 50,000 |
Cadavid Diego | SVP Clinical Development | 05/12/2020 | 8,984 |
Cadavid Diego | SVP Clinical Development | 05/12/2020 | 33,480 |
Thomson Peter G. | VP Finance & Accounting | 05/11/2020 | 120,000 |
Cadavid Diego | SVP Clinical Development | 03/02/2020 | 37,255 |
Thomson Peter G. | VP Finance & Accounting | 02/24/2020 | 84,153 |
Gould Robert J | See Remarks | 02/19/2020 | 50,000 |
Wallace Owen B. | Chief Scientific Officer | 02/19/2020 | 47,730 |
Wallace Owen B. | Chief Scientific Officer | 02/19/2020 | 121,760 |
Cadavid Diego | SVP Clinical Development | 02/03/2020 | 37,142 |
Thomson Peter G. | VP Finance & Accounting | 01/23/2020 | 86,102 |
Sanofi | 10% Owner | 07/22/2019 | 1,500,000 |
Third Rock Ventures IV, L.P. | 10% Owner | 07/22/2019 | 1,300,000 |
Third Rock Ventures III, L.P. | 10% Owner | 07/22/2019 | 1,300,000 |
6 Dimensions Capital, L.P. | 10% Owner | 07/22/2019 | 1,900,000 |
Casdin Capital, LLC | 10% Owner | 07/22/2019 | 2,217,495 |
LEVIN MARK J | Director | 07/22/2019 | 1,300,000 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | 11,609,704 | 1.22% | No change | Other |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,518,881 | 1.68% | -3.5% | Growth At A Reasonable Price |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,506,422 | 0.02% | -37.4% | Other |
BLACKROCK INC. | 1,561,866 | 0.00027% | 8.02% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 553,230 | 0.00039% | 3.5% | Other |
VIVO CAPITAL, LLC | 520,000 | 0.25% | Exited | Other |
D. E. SHAW & CO., INC. | 497,679 | 0.00294% | 124.93% | Other |
BALYASNY ASSET MANAGEMENT L.P. | 105,179 | 0.00133% | New | Event Driven |
RENAISSANCE TECHNOLOGIES LLC | 52,734 | 0.0004% | Exited | Other |
ALPS ADVISORS INC | 39,854 | 0.00212% | New | Other |
BLACKSTONE INC. | 19,216 | 0.00058% | No change | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View